

## Литература:

1. Connolly SJ, *et al.* Randomized Comparison of the Effects of Two Doses of Dabigatran Etexilate on Clinical Outcomes Over 4.3 Years: Results of the RELY-ABLE Double-blind Randomized Trial. CS.04. Clinical Science: Special Reports: Valvular Heart Disease, PAD, Atrial Fibrillation: International Perspectives. Presented on 7 November 2012 at the American Heart Association Scientific Sessions 2012.
2. Connolly SJ, *et al.* Dabigatran versus warfarin in patients with atrial fibrillation. *N Engl J Med.* 2009;**361**:1139-51.
3. Connolly SJ, *et al.* Newly identified events in the RE-LY trial. *N Engl J Med.* 2010;**363**:1875-6.
4. Hannon, N., *et al.* "Stroke Associated with Atrial Fibrillation – Incidence and Early Outcomes in the North Dublin Population Stroke Study." *Cerebrovascular Diseases.* 2010;**29**:43-49.
5. NHLBI website. "What is Stroke?" Available at: <http://www.nhlbi.nih.gov/health/health-topics/topics/stroke>. Accessed on: October 10, 2012.
6. Pradaxa European Summary of Product Characteristics, 2012
7. Boehringer Ingelheim data on file.
8. Eikelboom JW, *et al.* Does dabigatran improve stroke-prevention in atrial fibrillation? Reply to a rebuttal. *J Thromb Haemost.* 2010;**8**:1438–9.
9. Stewart S, *et al.* Cost of an emerging epidemic: an economic analysis of atrial fibrillation in the UK. *Heart.* 2004;**90**:286-92.
10. Lloyd-Jones DM, *et al.* Lifetime risk for development of atrial fibrillation: the Framingham Heart Study. *Circulation.* 2004;**110**:1042-6.
11. Fuster V, *et al.* ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation – executive summary. *Circulation.* 2006;**114**:700-52.
12. Global Atlas on Cardiovascular Disease Prevention and Control, World Health Organization in collaboration with the World Heart Federation and the World Stroke Organization 2011. Viewed May 2012 at [http://www.world-heart-federation.org/fileadmin/user\\_upload/documents/Publications/Global\\_CVD\\_Atlas.pdf](http://www.world-heart-federation.org/fileadmin/user_upload/documents/Publications/Global_CVD_Atlas.pdf).
13. Atlas of Heart Disease and Stroke, World Health Organization, September 2004. Viewed Dec 2010 at [http://www.who.int/cardiovascular\\_diseases/en/cvd\\_atlas\\_15\\_burden\\_stroke.pdf](http://www.who.int/cardiovascular_diseases/en/cvd_atlas_15_burden_stroke.pdf).
14. Wolf PA, *et al.* Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. *Stroke.* 1991;**22**:983-8.
15. Marini C, *et al.* Contribution of atrial fibrillation to incidence and outcome of ischaemic stroke: results from a population-based study. *Stroke.* 2005;**36**:1115-9.
16. Gladstone DJ, *et al.* Potentially Preventable Strokes in High-Risk Patients With Atrial Fibrillation Who Are Not Adequately Anticoagulated. *Stroke.* 2009;**40**:235-240.
17. Paolucci S, *et al.* Functional outcome of ischemic and hemorrhagic stroke patients after inpatient rehabilitation. *Stroke.* 2003;**34**:2861–5.
18. Petrea RE, *et al.* Gender differences in stroke incidence and poststroke disability in the Framingham Heart Study. *Stroke.* 2009;**40**:1032-7.
19. Meschia JF, *et al.* Genetic susceptibility to ischemic stroke. *Nat Rev Neurol.* 2011;**7**:369–78.
20. Andersen KK, *et al.* Hemorrhagic and ischemic strokes compared: stroke severity, mortality, and risk factors. *Stroke.* 2009;**40**:2068–72.
21. Roger VL, *et al.* AHA Statistical Update. Heart Disease and Stroke Statistics—2011 Update. A Report From the American Heart Association. *Circulation* 2011; **123**:e18–e209.
22. Hart RG, *et al.* Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation *Ann Intern Med.* 2007;**146**:857-67.
23. Coyne KS, *et al.* Assessing the direct costs of treating nonvalvular atrial fibrillation in the United States. *Value Health* 2006; **9**:348-56.
24. Ringborg A, *et al.* Costs of atrial fibrillation in five European countries: results from the Euro Heart Survey on atrial fibrillation. *Europace* 2008; **10**:403-11.
25. Brüggjenjürgen B, *et al.* The impact of atrial fibrillation on the cost of stroke: the Berlin acute stroke study. *Value Health* 2007;**10**:137-43.
26. Di Nisio M, *et al.* Direct thrombin inhibitors. *N Engl J Med* 2005; **353**:1028-40.
27. Инструкция по медицинскому применению лекарственного препарата Прадакса: ЛП 000872-181011
28. Ross Southworth M, *et al.* Dabigatran and postmarketing reports of bleeding. *New Eng J Med.* 2013; DOI: DOI: 10.1056/NEJMp1302834. Available at: <http://www.nejm.org>
29. Food and Drug Administration FDA Drug Safety Communication: Update on the risk for serious bleeding events with the anticoagulant Pradaxa. Viewed March 2013. Available at <http://www.fda.gov/Drugs/DrugSafety/ucm326580.htm>